Search Videos by Topic or Participant
Browse by Series:

Managing Skeletal-Related Events in Breast Cancer, Part II

Panelists: William J. Gradishar, MD, Northwestern;Joyce O’Shaughnessy, MD, Texas Oncology; Christy A. Russell, MD, USC Norris; Debu Tripathy, MD,
Published Online: Tuesday, Dec 11, 2012
For High-Definition, Click
One of the challenges facing the management of skeletal-related events (SREs) is determining the correct antiresorptive therapy and setting for women with breast cancer. Further complicating the issue, varying data and controversy exist concerning the use of calcium, vitamin D, and bisphosphonates.

Christy A. Russell, MD, notes that she uses the NCCN guidelines for clues about possible therapy options. In general, Russell notes that she waits until patients have become significantly osteopenic before initiating treatment with an oral bisphosphonate. She adds that in general a majority of patients are not taking calcium and vitamin D, which further complicates matters.

Debu Tripathy, MD, agrees that replacing calcium and vitamin D is an essential part of the equation that has become a controversial issue. He adds that evidence on the use of vitamin D is mixed, not just in terms of bone health but also concerning lowering breast cancer risk. Linda T. Vahdat, MD, notes that simple management of vitamin D deficiency can be handle by the oncologist and she recommends more complicated cases be referred to a specialists.

Tripathy notes that information regarding administering adjuvant bisphosphonates is mixed. In general, the panel agrees that these agents seem to be most effective in postmenopausal women or in the high-risk setting but may result in complications in younger premenopausal women.

View >>> Managing Skeletal-Related Events in Breast Cancer, Part I


Slider Left
Slider Right
For High-Definition, Click
One of the challenges facing the management of skeletal-related events (SREs) is determining the correct antiresorptive therapy and setting for women with breast cancer. Further complicating the issue, varying data and controversy exist concerning the use of calcium, vitamin D, and bisphosphonates.

Christy A. Russell, MD, notes that she uses the NCCN guidelines for clues about possible therapy options. In general, Russell notes that she waits until patients have become significantly osteopenic before initiating treatment with an oral bisphosphonate. She adds that in general a majority of patients are not taking calcium and vitamin D, which further complicates matters.

Debu Tripathy, MD, agrees that replacing calcium and vitamin D is an essential part of the equation that has become a controversial issue. He adds that evidence on the use of vitamin D is mixed, not just in terms of bone health but also concerning lowering breast cancer risk. Linda T. Vahdat, MD, notes that simple management of vitamin D deficiency can be handle by the oncologist and she recommends more complicated cases be referred to a specialists.

Tripathy notes that information regarding administering adjuvant bisphosphonates is mixed. In general, the panel agrees that these agents seem to be most effective in postmenopausal women or in the high-risk setting but may result in complications in younger premenopausal women.

View >>> Managing Skeletal-Related Events in Breast Cancer, Part I
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Advance the Treatment of Triple-Negative Breast Cancer: Examining the Evidence and Looking to the FutureFeb 28, 20171.5
Clinical Vignette Series: 33rd Annual Miami Breast Cancer Conference®May 18, 20172.0
Publication Bottom Border
Border Publication